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Recently, the use of oncolytic viruses in cancer therapy has become
a realistic therapeutic option. Seneca Valley Virus (SVV) is a newly
discovered picornavirus, which has earned a significant reputation
as a potent oncolytic agent. Anthrax toxin receptor 1 (ANTXR1),
one of the cellular receptors for the protective antigen secreted
by Bacillus anthracis, has been identified as the high-affinity cel-
lular receptor for SVV. Here, we report the structure of the SVV-
ANTXR1 complex determined by single-particle cryo-electron micros-
copy analysis at near-atomic resolution. This is an example of a shared
receptor structure between a mammalian virus and a bacterial toxin.
Our structure shows that ANTXR1 decorates the outer surface of the
SVV capsid and interacts with the surface-exposed BC loop and loop II
of VP1, “the puff” of VP2 and “the knob” of VP3. Comparison of the
receptor-bound capsid structure with the native capsid structure re-
veals that receptor binding induces minor conformational changes in
SVV capsid structure, suggesting the role of ANTXR1 as an attach-
ment receptor. Furthermore, our results demonstrate that the capsid
footprint on the receptor is not conserved in anthrax toxin receptor 2
(ANTXR2), thereby providing a molecular mechanism for explaining
the exquisite selectivity of SVV for ANTXR1.
cryo-electron microscopy | picornavirus | virus receptor interaction |
Seneca Valley Virus | cancer therapy
Seneca Valley Virus (SVV) is a small (∼30 nm in diameter)icosahedral virus harboring a positive-sense, single-stranded
RNA genome of 7.3 kb. The RNA genome encodes seven
nonstructural proteins—2A, 2B, 2C, 3A, 3B, 3C, and 3D—and
four capsid proteins—VP1, VP2, VP3, and VP4 (1–3). Several
studies have highlighted the capacity of SVV to preferentially
infect and kill tumor cells with neuroendocrine features without
resulting in detrimental off-target effects (4, 5). SVV has been
investigated for its antitumor activity in phase I clinical trials
against pediatric solid tumors and in phase II clinical trials
against small-cell lung cancers (SCLC) (6–8). The efficacy of
SVV treatment in oncovirotherapy has been shown to be limited
due to the host immune response within 3 wk of viral infusion
(7). There is increasing interest in the development of SVV
mutants, which can retain their capacity to bind and infect tumor
cells while bypassing the host antiviral immune response. Recently
published results from our own work and collaborators unveiled
anthrax toxin receptor 1 (ANTXR1), a type I transmembrane
protein, as the cellular receptor governing specificity for SVV
infection (9). In comparison with the second anthrax toxin re-
ceptor (ANTXR2), ANTXR1 is weakly expressed in normal
tissues but overexpressed in a wide variety of human tumors (10).
Little is known about the role of ANTXR1 in the development of
normal tissue, and studies of ANTXR1 knockout mice failed to
reveal any major phenotypic abnormalities (11). However, tumor
growth and tumor blood vessel density were significantly de-
creased in these mice (12). Moreover, in patients enrolled in a
phase I clinical study of SVV in advanced solid tumors with
neuroendocrine features, i.v. administration of the oncolytic virus
showed high specificity for tumor cells with no evidence of in-
fection and propagation in the surrounding normal tissue (6, 7). In
combination these studies provide a valuable strategy for selective
targeting of ANTXR1 overexpression in tumor cells with SVV
without impact on the adjacent normal tissue. However, the exact
locations and the nature of interactions between SVV and
ANTXR1 have not been characterized. Cryo-electron microscopy
(Cryo-EM) structure of SVV-ANTXR1 from this study identifies
surface-exposed loops of VP1, VP2, and VP3 as the sites of receptor
attachment. Furthermore, the atomic model of SVV-ANTXR1
complex shows residues participating in the capsid footprint on the
receptor are not conserved among ANTXR1 and ANTXR2, thereby
providing a plausible explanation for tumor specificity of SVV.
Findings from this study, in conjunction with future work on SVV-
antibody interaction sites, can provide a promising stage for the
development of SVV mutants with improved clinical applications.
Results
Overall Structure of SVV-ANTXR1 Complex. In this study, we used
cryo-electron microscopy (cryo-EM) single-particle analysis to
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study the interaction between SVV and the ANTXR1 receptor.
We used a fusion construct of ANTXR1 with the Ig Fc (fragment
crystallizable) region, since Fc has previously been reported to be
useful in improving the stability and solubility of bound partner
protein (13). The structure features a crown-like arrangement of
ANTXR1 around the fivefold axis of the capsid (Fig. 1A). The
strong electron potential corresponding to the receptor in our
3D reconstruction has a similar overall absolute value as the
electron potential inside the capsid (Fig. 1A and Movie S1),
suggesting that the equilibrium between the soluble ANTXR1
domain and the SVV-receptor complex in vitro is sufficient to
saturate most binding sites located on 60 asymmetric units. The
average radius of the receptor-decorated SVV capsid remains
unchanged at ∼150 Å as in the native structure, and no rear-
rangement of the capsid proteins was observed (Fig. 1B). The
largest radius of 210 Å spans from the center of the capsid to the
Fig. 1. Cryo-EM structure of the SVV-ANTXR1 complex. (A) Radially colored iso-potential surface of the reconstructed electron potential map, contoured at
2.4 σ above average, displayed along the icosahedral fivefold axis. ANTXR1 (blue) bound to SVV (green) demonstrates a “crown-like” arrangement around
the fivefold axis. (B) Central sections through normalized cryo-EM reconstructions of the undecorated full SVV capsid (left half, EMDB access code 7110) and of
the SVV-ANTXR1 complex (right half, present study). The capsid dimension does not change upon receptor binding. The capsid interior appears filled with
RNA in both reconstructions. (C) Atomic model in ribbon representation of ANTXR1 complexed to one capsid protomeric unit with VP1, VP2, VP3, VP4, and
ANTXR1 colored in blue, green, red, orange, and magenta, respectively. The same color scheme is used throughout the figures. (D) Segmented iso-electron
potential surfaces contoured at 2.4 σ of capsid proteins and ANTXR1. Refined side-chain conformations of a fitted atomic model show excellent corre-
spondence with the structure. (Scale bars: 100 Å.)
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Fc region at the tip of the attached ANTXR1 (Fig. 1B). Local
resolution estimation of the cryo-EM map indicates 3.1 Å
within the capsid structure, while the resolution within the
ANTXR1 domain is 4.25–4.75 Å (SI Appendix, Fig. S3 A and B)
and within the ANTXR1-linked Fc fragment >5 Å, suggesting
some flexibility of this region (SI Appendix, Fig. S1 A and B).
Overall, the map features corresponding to the polypeptide
chain and most of its side chains were of sufficient quality for
atomic model building of capsid proteins VP1–4 and the re-
ceptor region of the ANTXR-Fc fusion (Fig. 1 C and D and SI
Appendix, Table S1). The model was validated by building
two separate atomic models from independent maps as a
result of independent refinement and reconstruction (14); its
side chain conformations match the known polypeptide se-
quence in well-resolved areas, and it has been checked for
correct stereochemical geometry (SI Appendix, Figs. S2 and
S3 and Table S1).
Interactions Between SVV and ANTXR1. We determined the mech-
anism of interaction between SVV and ANTXR1 and localized
the receptor contact sites to surface-exposed loops on the virus.
The BC loop and loop II of VP1, the “puff” of VP2, and the
“knob” of VP3 (Fig. 1C) comprise an interface area of 742 Å2
on each ANTXR1-binding site. The involvement of all exte-
rior capsid proteins in receptor attachment is a phenomenon
consistent with most species in the Enterovirus genus (15–19).
Our refined atomic model of the SVV-ANTXR1 complex sug-
gests that hydrogen-bonding (H-bond) interactions are exclusive
to the VP1-ANTXR1 and VP2-ANTXR1 interfaces, whereas a
variety of amino acid interactions are shared among all three
interfaces. In VP1, the BC loop located at the center of the
icosahedral triangle and adjacent loop II establish contacts be-
tween helices α4 and α3 of ANTXR1, respectively (Fig. 2A). We
detected only one H-bond at the VP1-ANTXR1 interface,
formed between N94 on VP1 loop II and E122 on ANTXR1 α3
(Fig. 2A). The opposite end of the receptor is anchored to the
capsid near the icosahedral threefold axis by interactions estab-
lished between the α2–α3 loop of ANTXR1 and the knob of VP3
(Fig. 2B). Interestingly, the majority of the ANXTR1 footprint is
located on the puff loop of VP2 elevated between the BC loop
and loop II of VP1 (interface area ∼489 Å2) (Fig. 2 C and D).
The contact between ANTXR1 and the puff loop is stabilized by
H-bonds formed between Y160 on α4 and T180 and Y182 on the
puff (Fig. 2C). In addition, the puff loop interacts with helix
α3 and with loops α2–α3 and β2–β3 of ANTXR1 (Fig. 2 C
and D).
Changes in Capsid Proteins and the Receptor Post Interaction.
Picornaviruses, especially the members of the Enterovirus ge-
nus, undergo significant changes in capsid structure upon re-
ceptor binding, which is a prerequisite for the formation of the
“A-particle” (16–20). However, the existence of an A-particle
has not been reported for SVV or for members of the Aph-
thovirus genus, such as Foot and Mouth Disease Virus (FMDV).
Comparison of the atomic crystal structures of the native SVV
capsid and the receptor-decorated capsid from this study shows a
root-mean-square deviation (rmsd) of 0.88 in Cα positions (Fig.
3). Although the overall changes are subtle, several regions with
significant conformational changes can be distinguished in all
four SVV capsid proteins and ANTXR1 (SI Appendix, Fig. S4).
These changes are better understood by examining the fit of the
X-ray–based model with the refined asymmetric unit coordinates
in our cryo-EM map (Fig. 3). In VP1, the major differences are
observed in the N-terminal extension located at the interior of
the capsid close to the icosahedral fivefold axis (rmsd ∼1.6 Å)
(Fig. 3 A, 1). The first four residues are shifted by an average of 2 Å,
accounting for the largest deviation in this region. Interest-
ingly, the locally well-resolved map features suggest that
this region is not as disordered as in enteroviruses. Minor
changes in VP1 can be observed in the GH loop (residues 185–
215) located near the icosahedral twofold axis (rmsd 1.1 Å) (Fig.
3 A, 2). Even though the overall conformational changes in the
BC loop remain minimal, residues 58–64, which include
receptor-binding E63, are shifted by 1.3 Å in their Cα positions,
on average (SI Appendix, Fig. S4A). The largest changes within
VP2 are observed in the puff and the loop composed of residues
142–151 (Fig. 3 C, 1 and 2). Even though the changes observed in
the puff are minimal in general, residues 178–186, which con-
tribute to the bulk of receptor interactions, show considerable
shifts in their Cα positions (∼1 Å). A buried region that consists
of residues 142–151 undergoes the largest conformational al-
teration in VP2 (Fig. 3 C, 1) (rmsd ∼1.9 Å). Although this region
harbors the integrin-binding motif LDV (21), local conforma-
tional changes of this magnitude do not aid in exposing the
above-mentioned motif for ANTXR1 interaction. In addition,
the VP3 N-terminal extension located near the icosahedral
fivefold axis shows considerable conformational changes com-
pared with native structure (rmsd ∼1.3 Å) (Fig. 3 C, 1). Un-
surprisingly, the knob of VP3, which establishes van der Waals
interactions with ANTXR1, undergoes a major change—in
particular in the region composed of residues 62–67 that is
Fig. 2. Interactions between SVV capsid proteins and ANTXR1. All three
proteins located on the exterior of the capsid (VP1-3) are involved in re-
ceptor binding. Potential non–H-bond interactions and H-bond interactions
are illustrated in black dashed and red solid lines, respectively. (A) Residue
E63 on the BC loop of VP1 forms anion-π interactions with F159 on helix
⍺4 of ANTXR1. Our atomic model shows that residue N94 on loop II of
VP1 can H-bond with E122 on helix ⍺3 of ANTXR1. (B) Residue L113 on the
⍺2–⍺3 loop of ANTXR1 form potential van der Waals interactions with
S66 and the adjacent A65 on the knob of VP3. (C) Residues L157 and F159 on
helix ⍺4 of ANTXR1 form van der Waals interactions with P184 and T180 on
the puff of VP2, respectively. D156 adjacent to L157 on ANTXR1 participates
in establishing van der Waals interactions with L178 and P184 on the puff
loop. Potential H-bonds could be formed between Y160 on the ⍺4 helix and
T180 and two residues upstream with Y182. Furthermore, Y160 on ⍺4 helix is
in contact with P184 on the puff loop via aromatic interactions. (D) H121 on
⍺3 helix and Y119 on the ⍺2–⍺3 loop interact with P184 and P185 by
establishing aromatic and van der Waals interactions, respectively. T87 and
R88 on the β2–β3 loop are in contact with K171 and N186 on the puff loop
via electrostatic interactions.
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Fig. 3. Structural changes in capsid proteins and ANTXR1 post receptor binding. Changes in the structure of capsid proteins and ANTXR1 were determined by
calculating the shifts in C⍺ positions relative to the initial structure. Gray ribbons represent crystal structures (PDB ID codes 3CJI and 3N2N). Color scales
indicate degree of C⍺ rmsd (blue and red colors representing minimal and maximum changes, respectively). (A) N-terminal extension (1) (residues 1–31) and
GH loop of VP1 (2) (residues 185–215) deviate most. (B) Puff (residues 172–200) (1) and residues 142–151 (2) on CD loop are two surface-exposed regions on
VP2 with the highest conformational changes. (C) In VP3, N-terminal (1) residues (1–30) undergo moderate changes upon receptor binding. The knob (2)
(residues 57–73), which is involved in receptor interaction, shows significant conformational changes. (D) VP4 undergoes smaller conformational changes
compared with other capsid proteins (1, 2). VP4 is devoid of electron density corresponding to G63 (1), suggesting a disordering of this region upon receptor
binding. (E) Changes in ANTXR1 are observed in strands β1 and β3, helix ⍺6, and loop β5–⍺5.
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shifted closer to the α2–α3 loop of ANTXR1 by an average rmsd
of 1.8 Å. G63 in VP4, which has been reported to be in contact
with the RNA genome (2), was not well resolved in our cryo-EM
reconstruction, suggesting that this residue may become disor-
dered after interaction with the receptor (Fig. 3 D, 1). The loss of
order in VP4 G63 is accompanied by changes in RNA appear-
ance in the iso-electron potential map of the SVV-ANTXR1
complex (SI Appendix, Fig. S1C), which appears to be less
ordered in comparison with that of mature virions (2). Fea-
tures of RNA loops were visible only at lower contour levels in
our reconstruction. Compared with other capsid proteins,
VP4 largely retains its fold (rmsd ∼0.9 Å), except for the
missing G63 residue and residues 14–17, 35–38, and 64–65,
which shift by 1.3, 1.1, and 1.2 Å, respectively (Fig. 3 D, 1 and
2 and SI Appendix, Fig. S4D).
The changes in the ANTXR1 structure upon capsid attach-
ment are more significant (rmsd ∼1.2 Å) (Fig. 3E and SI Ap-
pendix, Fig. S4E). Interestingly, these changes are observed in
the strands β1 and β3, the helix α6, and the β5–α5 loop, which are
not in direct contact with capsid proteins (rmsd of 2.5, 2.5, 1.8,
and 2.7 Å, respectively). It is important to note that these indi-
vidual deviations represent the largest contribution to the overall
rmsd in the refined ANTXR1 model. Overall, the changes in
SVV capsid proteins and ANTXR1 post interaction remain
minimal and do not provide any significant insights into their
functional relevance.
Fig. 4. Comparison of SVV-binding footprint on ANTXR1 with corresponding regions on ANTXR2 and α2β1 integrin to understand the specificity of SVV to
ANTXR1. Ribbon diagrams illustrate the structures of (A) ANTXR1, (B) ANTXR2 and α2β1, and (C) α2β1 integrin colored in different shades of gray with
nonconserved regions of ANTXR1 highlighted in magenta. (D) Superimposed structures of ANTXR1, ANTXR2, and α2β1 integrin. (E) Aligned sequences of
ANTXR1, ANTXR2, and α2β1 integrin with capsid-binding sites indicated by red boxes. Residues depicted on black or gray backgrounds represent identical or
similar sequences, respectively. Diverging residues are displayed on a white background. (F) Conformational shifts in side chains of conserved residues in
ANTXR1 in comparison with ANTXR2. H-bond forming E122 and Y160 residues demonstrates the highest shifts of 3.2 and 2.7 Å in ANTXR2, thereby po-
tentially hindering their capacity to form H-bonds unlike ANTXR1. H121 and Y119 are the only two conserved residues in ANTXR2 that may establish in-
teractions with SVV similar to that of ANTXR1.
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Comparison of Capsid Footprint on ANTXR1 with ANTXR2 and Integrins.
Our structure provides the structural basis to explain the selectivity
of SVV to ANTXR1 over ANTXR2 and integrin receptors.
ANTXR2, which is abundantly expressed in normal tissues (22),
has a 10 times higher affinity for the protective antigen (PA) of
anthrax toxin than ANTXR1 (23, 24) and is responsible for its
internalization (22, 25, 26). Integrin receptors function as cell-
surface receptors for FMDV (27) and adopt an α/β open sheet
fold similar to that of ANTXR1 and ANTXR2 (28). When the
refined structure of ANTXR1 from our study (Fig. 4A) was
superimposed with crystal structures of ANTXR2 [Fig. 4B, Protein
Data Bank (PDB) ID code 1SHT] and α2β1 integrin (Fig. 4C,
PDB ID code 5HJ2), the three structures agreed very closely in
their overall fold (Fig. 4D). However, the sequences of
ANTXR1 and α2β1 integrin differ greatly from each other with
a sequence homology of only 15%, whereas ANTXR1 and
ANTXR2 share a closer sequence homology of 50% (Fig. 4E).
When comparing the footprint of ANTXR1 on the SVV capsid to
the corresponding regions on ANTXR2, we can distinguish both
conserved (Fig. 4A, gray ribbon) and nonconserved residues (Fig.
4A, pink ribbon). Residues 156, 157, 159 on helix α4; T87 and
R88 on the β2–β3 loop; and L113 on the α2–α3 loop constitute the
nonconserved residues on ANTXR1 that interact with SVV (Fig.
4 A and E). On the other hand, Y160 on helix α4; H121 and
E122 on helix α3; and Y119 on the α2–α3 loop fall into the con-
served residues that interact with SVV (Fig. 4 A and E). Never-
theless, the side-chain rotamers of E122 and Y160 are visibly
shifted in our experimental map of ANTXR1 (Fig. 4F), thereby
disfavoring the H-bond formation with N94 (VP1) and T180
(VP2), respectively. Side chains of H121 and Y119 located on
helix α3 are in similar locations in ANTXR2 and may therefore
interact with SVV as observed at the VP2-ANTXR1 interface.
However, these interactions alone may not be sufficient to es-
tablish a stable link between ANTXR2 and SVV to facilitate entry
into nontumorous host cells.
Discussion
In summary, our cryo-EM structure allowed us to explain how
SVV discriminates between ANTXR1 and ANTXR2. Sequence
comparison of ANTXR2 with ANTXR1 bound to SVV revealed
that most of the receptor residues contributing to virus-receptor
interactions are not conserved among the two receptors. Therefore,
this ensures specific targeting of tumors expressing ANTXR1 with
SVV, without causing any off-target effect on normal cells that
highly express ANTXR2. Interestingly, these residues were found
to be among the key amino acids governing the striking difference
in PA-binding affinities between ANTXR1 and ANTXR2 in pre-
vious studies (29).
Our findings reveal that the affinities of a mammalian virus
and a bacterial toxin to the same receptor are differentiated by
similar nonconserved regions at their virus-receptor– and toxin-
receptor–binding interfaces. Compared with other picornavi-
ruses currently investigated as potential oncolytic agents such as
poliovirus (30) and coxsackievirus (31), SVV has the valuable
advantage of a high-affinity cellular receptor that is also a widely
spread tumor marker. One major challenge in advancing SVV as
an oncolytic agent is the response of the patient’s immune re-
sponse. SVV is not a human pathogen. Therefore, there exists no
innate immunity in patients (6, 7). However, after 2–3 weeks
following virus administration, the host organism develops im-
munity, and the virus is cleared from the organism (6, 7). Hence,
it would be of major significance for future work to investigate
the interactions between SVV and neutralizing antibodies and to
identify key residues on the capsid surface involved in these in-
teractions. So far, the only information regarding SVV-antibody
interaction stems from the study of genetic variation of stock
pathogen SVV strains responsible for neonatal mortality and
vesicular lesions in pigs (3). In all of the different SVV strains
reported (3), the ANTXR1-binding site is highly conserved, except
for the E63T mutation on the BC loop of VP1. Of importance is
the ability of these strains to bypass recognition by neutralizing
monoclonal antibodies (3, 32). This observation suggests that the
ANTXR1-binding site on SVV may partially overlap with the
binding epitope of neutralizing antibodies. Future work will
involve investigating the interactions between SVV and neu-
tralizing antibodies to identify and mutate residues on the
capsid surface that interact with antibodies. Thus, the findings
from this study encourage the development of potent SVV mu-
tants in oncovirotherapy capable of evading the host immune re-
sponse, while retaining their ability to preferentially kill tumors.
Materials and Methods
Virus Production and Purification. SVV full capsids were purified according to
methods adapted from previously published protocols (2). Briefly, SCLC
H446wt cells (ATCC, HTB-171) were grown in Roswell Park Memorial In-
stitute medium (RPMI) 1640 (catalog no. 1851354; Gibco) supplemented with
10% (vol/vol) FBS and 1% (vol/vol) penicillin–streptomycin to ∼80% con-
fluency in eight T175 flasks. Cells were infected by replacing the existing
medium with RPMI medium 1640 containing 2% (vol/vol) FBS and plaque-
purified SVV stock at a multiplicity of infection of 1, followed by in-
cubation at 37 °C for 3 d. The detached cells after 3 d were treated with
0.05% (vol/vol) Triton ×100 in RPMI 1640 for 30 min at room temperature
to permeabilize cell membranes. Thereafter, the cell suspension was trans-
ferred into 250-mL Nalgene bottles and centrifuged at 10,000 × g for 30 min
at 4 °C. The resulting supernatant was transferred into six 38.5-mL open-top,
polypropylene tubes (catalog no. Z60105SCA; Beckman Coulter) and spun
down at 120,000 × g for 1 h in a Beckman Coulter SW32Ti rotor at 4 °C. After
discarding the supernatant, the virus pellet was resuspended in CsCl purifi-
cation buffer (137 mM NaCl, 5 mM KCl, 25 mM Tris base, 0.8 mM NaH2PO4,
pH 7.4) overnight at 4 °C. Suspended virus was loaded onto a 1.38-g/mL
isopycnic CsCl gradient prepared in a 16.5-mL open-top polypropylene tube
(catalog no. Z60303SCA; Beckman Coulter) and centrifuged at 61,580 × g for
18 h in a Beckman Coulter SW 32.1 Ti rotor at 22 °C. Viral bands were col-
lected and dialyzed against PBS buffer overnight at 4 °C. Final virus
concentration in dialyzed fraction was measured by a Qubit protein
concentration assay kit (catalog no. 1814929; Life Technologies). Samples
were stored at −80 °C until used.
SVV-ANTXR1 Interaction. The interaction between SVV and ANTXR1 was
carried out according to previously published protocols (9). In brief, SVV
purified from the previous step (0.2 mg/mL) was mixed with recombinant
human ANTXR1-Fc (1 mg/mL) (catalog no. 13367-H02H; Sino Biological) in
equal volumes. The virus-receptor mixture was incubated at 37 °C for 90 min,
followed by another 90 min incubation in an ice bath.
Cryo-EM Sample Preparation and Data Collection. Cryo-EM specimens were
prepared by applying 2.5–4.0 μL of SVV-ANTXR1 mixture from the above
step onto glow-discharged QF-1.2/1.3 grids (Quantifoil). Excess liquid was
blotted off on a Vitrobot IV (Thermo Fisher Scientific) at 100% humidity for
3 s with blot force 0, immediately followed by plunge-freezing the grid into
liquid ethane at liquid nitrogen temperature. Frozen grids were imaged at
73,000× magnification on a Talos Arctica cryo-transmission electron micro-
scope (Thermo Fisher Scientific) operating at 200 kV, with a Falcon III direct
electron detector (Thermo Fisher Scientific) in integrating mode at a dose
rate of 80 el/pixel/s. Images of grid areas with thin ice were recorded au-
tomatically following low-dose procedures with the EPU software (Thermo
Fisher Scientific) at a pixel size of 1.42 Å/pixel.
Image Processing and Single-Particle Analysis of the SVV-ANTXR1 Complex. A
total of 39 movie frames (each containing a dose of 1 el/Å2/frame) were
aligned, dose-weighted, and summed with MotionCor2 (33), resulting in a
total dose of 39 e−/Å2/image. Defocus estimation was performed with
Ctffind4 (34). Only micrographs with a good fit correlation to 4.0 Å were
used for single-particle analysis of the SVV-ANTXR1 complex. Manual par-
ticle selection was carried out in E2BOXER (35), yielding 7,457 single-particle
images. Subsequent 2D classification, 3D classification, and 3D refinement
were carried out with Relion 1.4 (36). Briefly, picked particles were extracted
with a box size of 420 pixels and were subjected to several rounds of reference-
free 2D classification. Good class averages were manually identified, and junk
particles were omitted. A selection of 6,782 good particles were subjected to
reference-based 3D classification by using a low-pass-filtered (50 Å) electron
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density map of the SVV crystal structure (PDB ID code 3CJI) as the initial 3D
model. The resulting experimental 3D model of the SVV-ANTXR1 complex
was further refined and postprocessed. Final overall resolution of the re-
construction was estimated as 3.8 Å between independently refined data sets
at a Fourier shell correlation of 0.143. A local resolution map was calculated
with Resmap (37).
Atomic Model Building and Refinement. The crystal structures of SVV (PDB ID
code 3CJI) and ANTXR1 (PDB ID code 3N2N) were used as starting models to
build the atomic model of the SVV-ANTXR1 complex. The aforementioned
crystal structures were fitted into the cryo-EMmap, firstmanually and then by
using the fitmap function of UCSF Chimera (38). One asymmetric unit and its
symmetry-related neighbors were selected and masked, and the surround-
ing map was excluded. Initial atomic coordinates were subjected to manual
rigid-body fitting into the segmented reconstruction with Coot (39). The
discrepancies between the atomic model and the cryo-EM map were further
minimized by subjecting the atomic model built with Coot to further re-
finement by Phenix (40) with the phenix.real_space_refine program. Model
refinement was carried out for five iterations until satisfactory model re-
finement statistics were obtained according to MolProbity (41). The model
was further validated by building independent atomic models for the two
half maps used in the 3D refinement and then comparing these models with
one another and with the atomic model built from the full map (14) (SI
Appendix, Fig. S2). Chimera and ChimeraX (42) were used as the primary
programs for visualization of structures and production of figures. The in-
teractions between SVV and ANTXR1 at the interface (SI Appendix, Fig. S5)
were elucidated using Chimera and JsPISA online server (www.ccp4.ac.uk/
pisa). Spherical projection of the receptor footprint on SVV was generated
using the program RIVEM (43).
Data Availability. The cryo-EM map of the SVV-ANTXR1 complex was de-
posited in the EMDataBank (EMDB) database under entry code 7772. Model
coordinates were uploaded to the Protein Data Bank with PDB access
code 6CX1.
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